Robust vascular protective effect of hydroxamic acid derivatives in a sickle mouse model of inflammation

Dhananjay K. Kaul, Rahn Kollander, Hemchandra Mahaseth, Xiao Du Liu, Anna Solovey, John D Belcher, Robert J. Kelm, Gregory M Vercellotti, Robert P Hebbel

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objective: Clinically, the vascular pathobiology of human sickle cell disease includes an abnormal state of chronic inflammation and activation of the coagulation system. Since these biologies likely underlie development of vascular disease in sickle subjects, they offer attractive targets for novel therapeutics. Similar findings characterize the sickle transgenic mouse, which therefore provides a clinically relevant inflammation model. Method: The authors tested two polyhydroxyphenyl hydroxamic acid derivatives, didox and trimidox, in sickle transgenic mice. Animals were examined by intravital microscopy (cremaster muscle and dorsal skin fold preparations) and by histochemistry before and after transient exposure to hypoxia, with versus without preadministration of study drug. Previous studies have validated the application of hypoxia/reoxygenation to sickle transgenic mice as a disease-relevant model. Results: Animals pretreated with these agents exhibited marked improvements in leukocyte/endothelial interaction, hemodynamics and vascular stasis, and endothelial tissue factor expression. Thus, these drugs unexpectedly exert powerful inhibition on both the inflammation and coagulation systems. Conclusions: Each of these changes is expected to be therapeutically beneficial in systemic inflammatory disease in general, and in sickle disease in particular. Thus, these novel compounds offer the advantage of having multiple therapeutic benefits in a single agent.

Original languageEnglish (US)
Pages (from-to)489-497
Number of pages9
JournalMicrocirculation
Volume13
Issue number6
DOIs
StatePublished - Sep 1 2006

Fingerprint

Hydroxamic Acids
Transgenic Mice
Blood Vessels
3,4-dihydroxybenzohydroxamic acid
Inflammation
Abdominal Muscles
Vascular Endothelium
Sickle Cell Anemia
Thromboplastin
Vascular Diseases
Pharmaceutical Preparations
Leukocytes
Hemodynamics
Skin
Therapeutics
Hypoxia

Keywords

  • Anti-inflammatory
  • Endothelium
  • Hydroxyurea
  • Leukocyte
  • Sickle
  • Tissue factor

Cite this

Robust vascular protective effect of hydroxamic acid derivatives in a sickle mouse model of inflammation. / Kaul, Dhananjay K.; Kollander, Rahn; Mahaseth, Hemchandra; Liu, Xiao Du; Solovey, Anna; Belcher, John D; Kelm, Robert J.; Vercellotti, Gregory M; Hebbel, Robert P.

In: Microcirculation, Vol. 13, No. 6, 01.09.2006, p. 489-497.

Research output: Contribution to journalArticle

Kaul, Dhananjay K. ; Kollander, Rahn ; Mahaseth, Hemchandra ; Liu, Xiao Du ; Solovey, Anna ; Belcher, John D ; Kelm, Robert J. ; Vercellotti, Gregory M ; Hebbel, Robert P. / Robust vascular protective effect of hydroxamic acid derivatives in a sickle mouse model of inflammation. In: Microcirculation. 2006 ; Vol. 13, No. 6. pp. 489-497.
@article{077ff5cc821947da80601df1cdeaf903,
title = "Robust vascular protective effect of hydroxamic acid derivatives in a sickle mouse model of inflammation",
abstract = "Objective: Clinically, the vascular pathobiology of human sickle cell disease includes an abnormal state of chronic inflammation and activation of the coagulation system. Since these biologies likely underlie development of vascular disease in sickle subjects, they offer attractive targets for novel therapeutics. Similar findings characterize the sickle transgenic mouse, which therefore provides a clinically relevant inflammation model. Method: The authors tested two polyhydroxyphenyl hydroxamic acid derivatives, didox and trimidox, in sickle transgenic mice. Animals were examined by intravital microscopy (cremaster muscle and dorsal skin fold preparations) and by histochemistry before and after transient exposure to hypoxia, with versus without preadministration of study drug. Previous studies have validated the application of hypoxia/reoxygenation to sickle transgenic mice as a disease-relevant model. Results: Animals pretreated with these agents exhibited marked improvements in leukocyte/endothelial interaction, hemodynamics and vascular stasis, and endothelial tissue factor expression. Thus, these drugs unexpectedly exert powerful inhibition on both the inflammation and coagulation systems. Conclusions: Each of these changes is expected to be therapeutically beneficial in systemic inflammatory disease in general, and in sickle disease in particular. Thus, these novel compounds offer the advantage of having multiple therapeutic benefits in a single agent.",
keywords = "Anti-inflammatory, Endothelium, Hydroxyurea, Leukocyte, Sickle, Tissue factor",
author = "Kaul, {Dhananjay K.} and Rahn Kollander and Hemchandra Mahaseth and Liu, {Xiao Du} and Anna Solovey and Belcher, {John D} and Kelm, {Robert J.} and Vercellotti, {Gregory M} and Hebbel, {Robert P}",
year = "2006",
month = "9",
day = "1",
doi = "10.1080/10739680600778456",
language = "English (US)",
volume = "13",
pages = "489--497",
journal = "Microcirculation",
issn = "1073-9688",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Robust vascular protective effect of hydroxamic acid derivatives in a sickle mouse model of inflammation

AU - Kaul, Dhananjay K.

AU - Kollander, Rahn

AU - Mahaseth, Hemchandra

AU - Liu, Xiao Du

AU - Solovey, Anna

AU - Belcher, John D

AU - Kelm, Robert J.

AU - Vercellotti, Gregory M

AU - Hebbel, Robert P

PY - 2006/9/1

Y1 - 2006/9/1

N2 - Objective: Clinically, the vascular pathobiology of human sickle cell disease includes an abnormal state of chronic inflammation and activation of the coagulation system. Since these biologies likely underlie development of vascular disease in sickle subjects, they offer attractive targets for novel therapeutics. Similar findings characterize the sickle transgenic mouse, which therefore provides a clinically relevant inflammation model. Method: The authors tested two polyhydroxyphenyl hydroxamic acid derivatives, didox and trimidox, in sickle transgenic mice. Animals were examined by intravital microscopy (cremaster muscle and dorsal skin fold preparations) and by histochemistry before and after transient exposure to hypoxia, with versus without preadministration of study drug. Previous studies have validated the application of hypoxia/reoxygenation to sickle transgenic mice as a disease-relevant model. Results: Animals pretreated with these agents exhibited marked improvements in leukocyte/endothelial interaction, hemodynamics and vascular stasis, and endothelial tissue factor expression. Thus, these drugs unexpectedly exert powerful inhibition on both the inflammation and coagulation systems. Conclusions: Each of these changes is expected to be therapeutically beneficial in systemic inflammatory disease in general, and in sickle disease in particular. Thus, these novel compounds offer the advantage of having multiple therapeutic benefits in a single agent.

AB - Objective: Clinically, the vascular pathobiology of human sickle cell disease includes an abnormal state of chronic inflammation and activation of the coagulation system. Since these biologies likely underlie development of vascular disease in sickle subjects, they offer attractive targets for novel therapeutics. Similar findings characterize the sickle transgenic mouse, which therefore provides a clinically relevant inflammation model. Method: The authors tested two polyhydroxyphenyl hydroxamic acid derivatives, didox and trimidox, in sickle transgenic mice. Animals were examined by intravital microscopy (cremaster muscle and dorsal skin fold preparations) and by histochemistry before and after transient exposure to hypoxia, with versus without preadministration of study drug. Previous studies have validated the application of hypoxia/reoxygenation to sickle transgenic mice as a disease-relevant model. Results: Animals pretreated with these agents exhibited marked improvements in leukocyte/endothelial interaction, hemodynamics and vascular stasis, and endothelial tissue factor expression. Thus, these drugs unexpectedly exert powerful inhibition on both the inflammation and coagulation systems. Conclusions: Each of these changes is expected to be therapeutically beneficial in systemic inflammatory disease in general, and in sickle disease in particular. Thus, these novel compounds offer the advantage of having multiple therapeutic benefits in a single agent.

KW - Anti-inflammatory

KW - Endothelium

KW - Hydroxyurea

KW - Leukocyte

KW - Sickle

KW - Tissue factor

UR - http://www.scopus.com/inward/record.url?scp=33748329451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748329451&partnerID=8YFLogxK

U2 - 10.1080/10739680600778456

DO - 10.1080/10739680600778456

M3 - Article

VL - 13

SP - 489

EP - 497

JO - Microcirculation

JF - Microcirculation

SN - 1073-9688

IS - 6

ER -